Key opinion leaders close the discussion by discussing results of ongoing clinical trials presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting, regarding the use of perioperative therapy in patients with breast cancer.

Data from the following clinical trials are discussed:

A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). (Khan, ASCO 2020 LBA2)

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).(Wang, ASCO 2020 Abstract 507)

Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). (Harbeck, ASCO 2020 Abstract 500)

Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial. (van der Voort, ASCO 2020 Abstract 501)

MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. (Cardoso, ASCO 2020 Abstract 506)

Videos

Perioperative Therapy: ASCO 2020 Data Updates

A discussion on various ongoing clinical trials regarding the management of metastatic triple-negative breast cancer.

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. (Cortes, ASCO 2020 Abstract 1000)

TBCRC 048: A phase II study of olaparib in metastatic breast cancer patients with germline or somatic mutations in DNA damage response pathway genes (Olaparib Expanded). (Tung, ASCO 2020 Abstract 1002)

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer and/or germline BRCA-associated breast cancer (SWOG S1416). (Sharma, ASCO 2020 Abstract 1001)

Metastatic Triple-Negative Breast Cancer Ongoing Trials

Key opinion leaders discuss various trial data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting regarding the management of metastatic HER2-positive breast cancer.

Data from the following clinical trials is discussed:

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).(Lin, ASCO 2020 Abstract 1005)

The recent FDA approvals for relapsed refractory HER2+ MBC:

Trastuzumab deruxtecan in Previously Treated HER2+ Breast Cancer: DESTINY-BREAST01 (Modi, NEJM 2020)

The potential role of trastuzumab deruxtecan in HER2-low expressing tumors: phase 3, DESTINY-Breast04; NCT03734029

ASCO 2020 Data Updates: Metastatic HER2+ Breast Cancer

Experts in the management of breast cancer consider data updates presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting regarding metastatic HR-positive breast cancer.

PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with ER[+]/HER2[-] metastatic breast cancer. (Borrego, ASCO 2020 Abstract 1007)

Alpelisib + fulvestrant in patients with PIK3CA-mutated HR+/HER2– advanced breast cancer (ABC) previously treated with CDK 4/6 inhibitor + aromatase inhibitor: BYLieve study results.(Rugo, ASCO 2020 Abstract 1006)

Sara Tolaney, MD, MPH, Dana-Farber Harvard Cancer Center

Articles

Perioperative Therapy: ASCO 2020 Data Updates

Metastatic Triple-Negative Breast Cancer Ongoing Trials

ASCO 2020 Data Updates: Metastatic HER2+ Breast Cancer

Metastatic HR+ Breast Cancer Updates